Skip to main content Skip to navigation
Menu
800-789-7366

Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
John A. Kosteva, MD

John A. Kosteva, MD Physician

Clinical Assistant Professor of Medicine

Dr. Kosteva is employed by Penn Medicine.

Request a Callback
4.8out of 5
149 Patient Satisfaction Ratings

About Dr. John A. Kosteva

Recognized by America's Top Doctors 2015 - 2017

Recognized in Philadelphia magazine's annual Top Docs issues for 2018 and 2019

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2011
  • Medical Oncology, 2009

Clinical Expertise:

  • Anal Cancer
  • Anemia
  • Bladder Cancer
  • Breast Cancer
  • Esophageal Cancer
  • Hodgkin Lymphoma
  • Kidney Cancer
  • Lung Cancer
  • Lymphoma
  • Managing Cancer Treatment Side Effects
  • Mesothelioma
  • Mouth Cancer (Oral Cancer)
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Skeletal Metastasis
  • Small Cell Lung Cancer
  • Stomach Cancer (Gastric Cancer)
  • Thoracic Cancer
  • Throat Cancer
  • Thymoma and Thymic Carcinoma
  • Uterine Cancer
  • Waldenstrom Macroglobulinemia (WM)
View More

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Temple University School of Medicine
Residency: Temple University Hospital
Fellowship: Fox Chase Cancer Center
Fellowship: Temple University Hospital

Memberships

American Society of Clinical Oncology, National American Society of Hematology, National

Hospital Affiliation

Dr. Kosteva is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.

Research

Selected Publications:

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25. : 2017.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.: Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6. : 2016.

Kosteva J, Langer C: The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Current Opinion in Oncology 20 (2): 155-161,2008.

Kosteva J, Langer C: Skeletal metastases: Optimal management in 2007. Supportive Care in Cancer Therapy : 2008.

Kosteva J, Langer C: The changing landscape of non-small cell lung cancer: Economic consequences of skeletal metastases. New Directions in the Treatment of Lung Cancer 1 (4): 1-9,2005.

Kosteva J, Langer C.: Skeletal metastases in NSCLC: A retrospective review. 4th Annual ECOG/Aventis Young Investigator Symposium : 2004.

Kosteva J, Langer C: Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 46 (Suppl 1): S45,2004.

Kosteva J, Langer C: Skeletal metastases of non-small cell lung cancer: Advancements in diagnosis and treatment. Lung Cancer Principles and Practice Updates 4 (2): 1-14,2004.

Academic Contact Info

Abramson Cancer Center at Valley Forge
Division of Hematology/Oncology
1001 Chesterbrook Blvd.
Berwyn, PA 19312
Phone: (610) 576-7660
Patient appointments: 800-789-7366 (PENN)